ENहिन्दी soon
Home/India/Answers/Metformin and weight loss
INIndia Diabetes

Does metformin cause weight loss?

GLP Guidebook teamUpdated 5 Oct 202614 sourcesWritten from published sources
The short answer

A little, on average. In the US Diabetes Prevention Program, adults with raised blood sugar but no diabetes lost 2.1 kg on metformin over 2.8 years. Those on a dummy pill lost 0.1 kg. Stomach upset was more common on metformin. Metformin's US label lists type 2 diabetes only, and we found no Indian approval for weight loss.

How much weight do people lose on metformin?

In a large US trial of adults without diabetes, people on metformin lost about 2 kg more than those on a dummy pill.

The Diabetes Prevention Program (DPP) included 3,234 US adults with raised blood sugar who did not have diabetes. Each got metformin 850 mg twice a day, a dummy pill (placebo) or a lifestyle programme.1 Their average BMI (a weight-for-height score) was 34.1 Over 2.8 years, the metformin group lost 2.1 kg, the placebo group 0.1 kg and the lifestyle group 5.6 kg.1

Over about 10 years of follow-up, the metformin group stayed 2.0% below their starting weight, against 0.2% on placebo.2 The most regular pill-takers kept off 3.5% (3.1 kg).2 At 2 years, 26% on metformin had lost 5% or more, against 14% on placebo.2

Does metformin cause weight loss in diabetes, or in Indians?

In type 2 diabetes the effect looks small, because the US label's trial of metformin against a dummy pill found almost no difference.

In that 29-week trial, people on metformin lost 1.4 lb (0.6 kg) and those on placebo 2.4 lb (1.1 kg).3 A second 29-week label trial switched people from glyburide (another diabetes pill) to metformin alone. They lost 8.4 lb (3.8 kg), against 0.7 lb on glyburide.3 The American Diabetes Association (2026) calls it "neutral (potential for modest loss)".4

India's IDPP-1 trial split 531 Indians with raised blood sugar after a glucose drink into four groups, two of them on metformin.5 Over 3 years, new diabetes was 55.0% in the control group and 40.5% on metformin alone.5 The summary we could open reports no weight results.5

RisksThe risks of metformin, in brief
  • Stomach effects are common. Diarrhoea in 53% on metformin vs 12% on placebo in the US label trial.3 In the DPP they faded over time.2
  • Low vitamin B12. About 7% fell below normal in 29-week trials.3 "Common" (1 in 10 to 1 in 100) on the EU label for Jentadueto, a metformin combination.6
  • Lactic acidosis, an acid build-up in the blood. "Very rare" (under 1 in 10,000) on EU metformin leaflets,7 but it has caused deaths.3 Kidney or liver problems and heavy drinking raise the risk.3
  • Low blood sugar (hypos) is likelier with insulin or a sulfonylurea (a diabetes pill that makes the body release more insulin).3
GLP‑1 risks: Guide 5, Side effects and risks →
Get help now: call 112 if someone on metformin has trouble breathing, feels very weak, sleepy or cold, has a slow or irregular heartbeat, or has stomach pain and vomiting. These can be signs of lactic acidosis, which the US label calls a medical emergency.3

Is metformin approved for weight loss in India?

No. We found no Indian approval for weight loss, and the US label lists only blood-sugar control in type 2 diabetes.3

Metformin is missing from the table of approved weight medicines in India's ESI 2025 obesity guideline.8 In 2022, a CDSCO expert committee backed one firm's (USV) slow-release metformin tablets for delaying type 2 diabetes.9 The recommendation covers overweight, high-risk adults still heading towards diabetes after 3–6 months of intensive lifestyle change. It is not a weight-loss indication.9

For polycystic ovary syndrome (PCOS), a 2023 international guideline says metformin "should be considered" at BMI 25 or more, on very low-certainty evidence.10 More is in our PCOS weight-loss post. All the options sit side by side in Guide 3: Your options.

Before you go further
  • GLP‑1 medicines are prescription-only in India, not sold over the counter.11
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.11 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.12
  • The risks are in Guide 5: Side effects and risks.
  • Nothing here promises any result.

How does metformin compare with GLP-1 medicines for weight?

GLP-1 medicines gave far bigger average losses in their own trials, though those trials did not test them against metformin.

In STEP 1, semaglutide 2.4 mg (the Wegovy dose) cut weight by 14.9% vs 2.4% on placebo over 68 weeks.13 In SURMOUNT-1, tirzepatide 15 mg (the top Zepbound dose; Mounjaro is the same drug) cut 20.9% vs 3.1% over 72 weeks.14 Both trials left out people with diabetes. Stomach effects such as nausea were the most common side effects.13,14 India's ESI 2025 guideline also lists pancreatitis, gallstones and kidney injury among their warnings.8 The full trial picture is in How much weight do people lose on Ozempic or Mounjaro?

Read the full picture

Related questions

Can you take metformin and Ozempic together? Can you take Ozempic if you don't have diabetes? Is “GLP 1mg” tablet a GLP-1 medicine? Is Ozempic used for PCOS? Is Ozempic safe?
Did this answer your question?

Sources

  1. Diabetes Prevention Program Research Group (Knowler WC et al). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. doi:10.1056/NEJMoa012512 · PMID 11832527 · full text (PMC)
  2. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;35(4):731-737. doi:10.2337/dc11-1299 · PMID 22442396 · full text (PMC)
  3. Laurus Labs. Metformin hydrochloride tablets, US prescribing information and Medication Guide (DailyMed), revised 7/2026. Boxed warning; sections 1, 5.2, 5.3, 6.1 (Table 1), 14. US label, not an Indian one. dailymed.nlm.nih.gov
  4. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S183-S215. Table 9.2. doi:10.2337/dc26-S009 · PMID 41358900 · full text (PMC)
  5. Ramachandran A et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-297. Abstract. doi:10.1007/s00125-005-0097-z · PMID 16391903
  6. European Medicines Agency. Jentadueto (linagliptin/metformin): summary of product characteristics, section 4.8, Table 2 (reactions marked as metformin's own). EU label. ema.europa.eu
  7. European Medicines Agency. Metformin and metformin-containing medicines, Article 31 referral: Annex III, amendments to the product information (European Commission decision 12 Dec 2016). Package leaflet, section 4. ema.europa.eu
  8. Madhu SV, Kapoor N, Das S, Raizada N, Kalra S. ESI clinical practice guidelines for the evaluation and management of obesity in India: an update (2025). Indian J Endocrinol Metab 2025. Table 1. doi:10.4103/ijem.ijem_680_25 · PMID 40917319
  9. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 86th meeting, 26 and 29 Apr 2022, item 5: M/s USV's metformin hydrochloride sustained-release tablets 500/850/1000 mg, additional indication (pre-diabetes) recommended for approval. cdsco.gov.in · archived copy
  10. Teede HJ et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2023;38(9):1655-1679. Recommendation 4.3.1. doi:10.1093/humrep/dead156 · full text (PMC)
  11. PIB Research (Government of India). GLP-1 drugs: use, risks, and regulation. 1 Apr 2026. Key takeaways; "Regulation of GLP-1 drugs". static.pib.gov.in
  12. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism): 20–21 Apr 2023, item 1, tirzepatide (cdsco.gov.in · archived copy); 13–14 Feb 2024, items 3–4, semaglutide (cdsco.gov.in · archived copy).
  13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. Funded by Novo Nordisk. doi:10.1056/NEJMoa2032183 · PMID 33567185
  14. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. Sponsored by Eli Lilly (NCT04184622). doi:10.1056/NEJMoa2206038 · PMID 35658024

Last checked 5 Oct 2026 · Next review due 5 Oct 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write